Aspirin (NSC 27223)

Name: Aspirin (NSC 27223)
Brand: Selleck Chemicals
SKU: S3017
Rating: 5 (16 reviews)

For research use only.

Catalog No.S3017 Synonyms: Acetylsalicylic acid, ASA

16 publications

CAS No. 50-78-2

Aspirin (NSC 27223, Acetylsalicylic acid, ASA) is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.

Selleck's Aspirin (NSC 27223) has been cited by 16 publications

Dev Cell, 2021, S1534-5807(21)00485-8

PubMed: 34197724 ( click the link to review the publication )

Int Immunopharmacol, 2021, 95:107558

PubMed: 33743316 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

Immunity, 2020, 52(2):328-341

PubMed: 32049050 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Nanotoxicology, 2020, 14(2):162-180

PubMed: 31703536 ( click the link to review the publication )

Mol Oncol, 2020, 14(6):1152-1169

PubMed: 32239624 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Cell Death Dis, 2018, 9(8):809

PubMed: 30042442 ( click the link to review the publication )

Clin Chem Lab Med, 2018, 56(5):e118-e120

PubMed: 29306911 ( click the link to review the publication )

Sci Rep, 2017, 7(1):13846

PubMed: 29061995 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0185675

PubMed: 29023589 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 285(1):51-60

PubMed: 25841593 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1115-27

PubMed: 25303541 ( click the link to review the publication )

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description

Targets

COX2 ^[1]

COX1 ^[1]

In vitro

Aspirin inhibits the activation of NF-kappa B, thus prevents the degradation of the NF-kappa B inhibitor, I kappa B, and therefore NF-kappa B is retained in the cytosol. Aspirin also inhibits NF-kappa B-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells. ^[1] Aspirin and salicylate are mediated in part by their specific inhibition of IKK-beta, thereby preventing activation by NF-kappaB of genes involved in the pathogenesis of the inflammatory response. ^[2] Aspirin is protective against neurotoxicity elicited by the excitatory amino acid glutamate in rat primary neuronal cultures and hippocampal slices. ^[3] Aspirin triggers transcellular biosynthesis of a previously unrecognized class of eicosanoidsduring coincubations of human umbilical vein endothelial cells (HUVEC) and neutrophils [polymorphonuclear leukocytes (PMN)]. Aspirin evokes a unique class of eicosanoids formed by acetylated PGHS-2 and 5-lipoxygenase interactions. ^[4] Aspirin treatment inhibits the phosphorylation of IRS-1 at Ser307 as well as the phosphorylation of JNK, c-Jun, and degradation of IkappaBalpha in 3T3-L1 and Hep G2 cells treated with tumor necrosis factor (TNF)-alpha. Aspirin treatment inhibits phosphorylation of Akt and the mammalian target of rapamycin (but not extracellular regulated kinase or PKCzeta) in response to TNF-alpha. Aspirin rescues insulin-induced glucose uptake in 3T3-L1 adipocytes pretreated with TNF-alpha. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
AGS	MYLGeY5kfGmxbjDhd5NigQ>?	M2D6PVE2KHSxIE[wJJVud2xxTDDh[pRmeg>?	M3LyXVEzKGi{cx?=	M3LZ[GlvcGmkaYTpc44hd2ZiRYPjbIVzcWOqaXGgZ49tcS2\|dHnteYxifGWmIFnMMVgheHKxZIXjeIlwdiCrbjDoeY1idiCDR2OgZ4VtdHNiYYSgNVUhfG9iNkCgeY1wdC:OIHHmeIVzKDF{IHjyd{BjgSCHTFnTRS=>	NEP4fGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG1N\|E5Oyd-MkCxOVMyQDN:L3G+
microglia cells	Mmq0RY51cW6ndYLvbY5ndGGvbXH0c5J6KGG\|c3H5		NH[3cHAyPSCvaX7z	MVTBcpRqdmW3cn;pcoZt[W2vYYTvdpkh[WO2aY\peJkhcW5iTGDTMZN1cW23bHH0[YQhemG2IH3pZ5Jw\2yrYTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFCPQT3zeIlufWyjdHXkJHRZSjJicnXs[YF{\SCycnXpcoN2[mG2ZXSg[o9zKDF3IH3pcpMhdWWjc4Xy[YQhPzBibXnud{Bi\nSncjDQUWEh[2ijbHzlcodmNCCLQ{WwQVMvOTMQvF2=	NVHoT5JvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOVM5PzRpPkKyNVU{QDd2PD;hQi=>
HCT116	MWXGeY5kfGmxbjDhd5NigQ>?	NWG3R3N{OSCvTR?=	MmnLOkBpenN?	MV7Jcohq[mm2aX;uJI9nKFSQRj3hcJBp[S2rbnT1Z4VlKE6ILXvhdJBiSiCjY4TpeoF1cW:wIHnuJIh2dWGwIFjDWFEyPiClZXzsd{BifCBzIH3NJIFnfGW{IE[gbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=>	NFHrUnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG1OFg{PCd-MkKxOVQ5OzR:L3G+
SKBR3	NHzNVI5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MV:zNFAhfU1?	MYi0PEBpenN?	M{G1PWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMSlJ\|IHPlcIx{KGG2IEOwNEB2VSCjZoTldkA1QCCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZk>	NIHMXpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkS5OFYyPyd-MkK0PVQ3OTd:L3G+
PANC1	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NWDncXBPOzByIIXN	M4rR[FQ5KGi{cx?=	MYXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDQRW5EOSClZXzsd{BifCB\|MECgeW0h[W[2ZYKgOFghcHK\|IHL5JIFt[W2jcjDicJVmKGG\|c3H5	Mli5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OUS2NVcoRjJ{NEm0OlE4RC:jPh?=
PC3	NFnBOVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M2Tjc\|MxOCC3TR?=	MlnFOFghcHK\|	MXLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDQR\|Mh[2WubIOgZZQhOzByIIXNJIFnfGW{IES4JIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeR?=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR7NE[xO{c,OjJ2OUS2NVc9N2F-
MDA-MB-231	NYjucGpITnWwY4Tpc44h[XO\|YYm=	M3[xblExOCC3TR?=	M{C4O\|MxKG2rboO=	MVvJdpJmfmW{c3nicIUhcW6qaXLpeIlwdiCxZjDDU3guOSCrbjDoeY1idiCPRFGtUWIuOjNzIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh[XKjY3jp[I9vcWNiYXPp[E1qdmS3Y3XkJHBITTJiZn;ycYF1cW:wIHH0JFExOCC3TTDpcoN2[mG2ZXSg[o9zKDNyIH3pcpMh\m:ubH;3[YQh[nliY3;tdI92dmRid3HzbI92fCCvZXHzeZJm\CB\|MDDtbY5{KHCxc4SgZZJi[2irZH;ubYMh[WOrZDDjbIFtdGWwZ3WgZpkhemGmaX;pcY12dm:jc4PhfS=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ3MUO1PUc,OjN4NUGzOVk9N2F-
THP1	Mo\LSpVv[3Srb36gZZN{[Xl?	MVmxNFAhfU1?	NETGWHg{OCCvaX7z	NVi4SYt2UXK{ZY\ldpNq[mynIHnubIljcXSrb36gc4YhS0:[LUGgbY4hcHWvYX6gWGhROSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIFz[WOqaXTvcolkKGGlaXStbY5lfWOnZDDUXGIzKG[xcn3heIlwdiCjdDCxNFAhfU1iaX7jeYJifGWmIH\vdkA{OCCvaX7zJIZwdGyxd3XkJIJ6KGOxbYDveY5lKHejc3jveZQhdWWjc4Xy[YQhOzBibXnud{Bxd3O2IHHyZYNpcWSxbnnjJIFkcWRiY3jhcIxmdmenIHL5JJJi\GmxaX3teY5w[XO\|YYm=	M3faRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkWxN\|U6Lz5{M{[1NVM2QTxxYU6=
HCT116	NYjVRWs1S3m2b4TvfIlkcXS7IHHzd4F6		NVvQN4ZEPDhiaILz	M2nWfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KE2WVDDhd5NigQ>?	Mm\HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NUC0NFEoRjJ4N{WwOFAyRC:jPh?=
H9c2	M2DLRWNiemSrb4Dyc5Rm[3SrdnWgZZN{[Xl?	M2PKb\|EhfU1?	NYDvNWZPQCCqcoO=	MnjtR4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KG2nZHnheIVlKGmwZnzhcY1ifGmxbjDpckBz[XRiSEnjNkBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDJUE03KGmwIIP1dIVzdmG2YX70JIF1KDFidV2gdJJmcW6ldXLheIVlKG[xcjC4JIhzeyCob3zsc5dm\CCkeTDINm8zKGGmZHn0bY9vKG[xcjCyJIhzeyCkeTDFUGlUSQ>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O\|E9N2F-
H9c2	NHXXbZhE[XKmaX;wdo91\WO2aY\lJIF{e2G7	NGGwSngyKHWP	M4S5SVghcHK\|	NGDGZ21E[XKmaX;wdo91\WO2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJlxd3irYT3pcoR2[2WmIH;4bYRifGm4ZTDzeJJme3NibXXkbYF1\WRiaX7mcIFudWG2aX;uJIlvKHKjdDDIPYMzKGOnbHzzJIF{e2W\|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJHRPTi2jbIDoZUBqdiC\|dYDldo5ifGGwdDDheEAyKHWPIIDy[Ylv[3WkYYTl[EBnd3JiODDodpMh\m:ubH;3[YQh[nliSELPNkBi\GSrdHnvckBnd3JiMjDodpMhcW5icILld4Vv[2Vib3[gcIVwdnW{aX7lJIJ6KEV?	NWjh[ZNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O\|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2	NFL3S4RE[XKmaX;wdo91\WO2aY\lJIF{e2G7	MmS5NUB2VQ>?	NXXJRZd3QCCqcoO=	MVXDZZJlcW:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiaInwc5hq[S2rbnT1Z4VlKG:6aXTheIl3\SC\|dILld5MhcW5icnH0JGg6[zJiY3XscJMh[XO\|ZYPz[YQh[XNiYX70bY95cWSjboSgZYN1cX[rdImgZpkhdWWjc4XybY5oKHKnZIXjeIlwdiCrbjDNSGEhdGW4ZXzzJIF1KDFidV2gdJJmcW6ldXLheIVlKG[xcjC4JIhzeyCob3zsc5dm\CCkeTDINm8zKGGmZHn0bY9vKG[xcjCyJIhzeyCkeTDzdIVkfHKxcHjveI9u\XS{eR?=	M{GyOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2	Ml;VR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>?	NGraT44yKHWP	M{ja[lghcHK\|	MWPDZZJlcW:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiaInwc5hq[S2rbnT1Z4VlKG:6aXTheIl3\SC\|dILld5MhcW5icnH0JGg6[zJiY3XscJMh[XO\|ZYPz[YQh[XNiYX70bY95cWSjboSgZYN1cX[rdImgZpkhdWWjc4XybY5oKGmwY4LlZZNmKGmwIGPPSEBi[3Srdnn0fUBifCBzIIXNJJBz\WmwY4XiZZRm\CCob4KgPEBpenNiZn;scI94\WRiYomgTFJQOiCjZHTpeIlwdiCob4KgNkBpenNiYomgd5Bm[3S{b4Doc5RwdWW2com=	Mke0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3N{W0O\|EoRjJ5NUe1OFcyRC:jPh?=
H9c2	Ml34R4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>?	MVexJJVO	MVu4JIhzew>?	NYDIXVhpS2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDvfIll[XSrdnWgd5Rz\XO\|IHnuJJJifCCKOXOyJINmdGy\|IHHzd4V{e2WmIHHzJIFvfGmxeHnkZY51KGGldHn2bZR6KGK7IH3lZZN2emmwZzDpcoNz\WG\|ZTDpckBk[XSjbHHz[UBi[3Srdnn0fUBifCBzIIXNJJBz\WmwY4XiZZRm\CCob4KgPEBpenNiZn;scI94\WRiYomgTFJQOiCjZHTpeIlwdiCob4KgNkBpenNiYomgd5Bm[3S{b4Doc5RwdWW2com=	NWLGNo83RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O\|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2	MoHMR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>?	NXX4NJlxOSC3TR?=	MY[4JIhzew>?	M4fkbWNiemSrb4Dyc5Rm[3SrdnWgZYN1cX[rdImgZYdicW6\|dDDofZBwgGmjLXnu[JVk\WRib4jp[IF1cX[nIIP0doV{eyCvZXTpZZRm\CCrbn\sZY1u[XSrb36gbY4hemG2IFi5Z\|Ih[2WubIOgZZN{\XO\|ZXSgZZMhe3WycILld5Nqd25ib3[gWG5HNWGucHjhJIlvKHO3cHXycoF1[W62IHH0JFEhfU1icILlbY5kfWKjdHXkJIZweiB6IHjyd{Bnd2yub4fl[EBjgSCKMl:yJIFl\Gm2aX;uJIZweiB{IHjyd{BjgSCHTFnTRS=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O\|E9N2F-
H9c2	M1eybWNiemSrb4Dyc5Rm[3SrdnWgZZN{[Xl?	NHqycJMyKHWP	MnTLPEBpenN?	MnjiR4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCxeHnkZZRqfmVic4Ty[ZN{KG2nZHnheIVlKGmwZnzhcY1ifGmxbjDpckBz[XRiSEnjNkBk\WyuczDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjDJUE0y[mW2YTDpckB{fXCncn7heIFvfCCjdDCxJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhQCCqcoOg[o9tdG:5ZXSgZpkhUDKRMjDh[IRqfGmxbjDmc5IhOiCqcoOgZpkhTUyLU1G=	NYD6SHRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O\|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2	M3:2[GNiemSrb4Dyc5Rm[3SrdnWgZZN{[Xl?	MWGxJJVO	MlrhPEBpenN?	MWXDZZJlcW:ycn;0[YN1cX[nIHHjeIl3cXS7IHHnZYlve3RiaInwc5hq[S2rbnT1Z4VlKG:6aXTheIl3\SC\|dILld5MhcW5icnH0JGg6[zJiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJG1FSSCuZY\lcJMh[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFghcHK\|IH\vcIxwf2WmIHL5JGgzVzJiYXTkbZRqd25iZn;yJFIhcHK\|IHnuJJBz\XOnbnPlJI9nKGynb371dolv\SCkeTDzdIVkfHKxcHjveI9u\XS{eR?=	M{XIW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
H9c2	MmnSR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>?	M4fsd\|EhfU1?	MUe4JIhzew>?	NFrV[ndE[XKmaX;wdo91\WO2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJlxd3irYT3pcoR2[2WmIH;4bYRifGm4ZTDzeJJme3NiaX6gdoF1KEh7Y{KgZ4VtdHNiYYPz[ZN{\WRiYYOgZY51cW:6aXThcpQh[WO2aY\peJkh[nlibXXhd5VzcW6pIHnuZ5Jm[XOnIHnuJHNQTCCjY4Tpeol1gSCjdDCxJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhQCCqcoOg[o9tdG:5ZXSgZpkhUDKRMjDh[IRqfGmxbjDmc5IhOiCqcoOgbY4heHKnc3XuZ4Uhd2ZibHXvcpVzcW6nIHL5JJNx\WN?	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzV5NUS3NUc,Ojd3N{W0O\|E9N2F-
H9c2	MYPDZZJlcW:ycn;0[YN1cX[nIHHzd4F6	NXXCTlQ{OSC3TR?=	NG\qOIw5KGi{cx?=	NEjv[mxE[XKmaX;wdo91\WO2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJlxd3irYT3pcoR2[2WmIH;4bYRifGm4ZTDzeJJme3NibXXkbYF1\WRiaX7mcIFudWG2aX;uJIlvKHKjdDDIPYMzKGOnbHzzJIF{e2W\|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJGlNNTZiaX6gd5Vx\XKwYYThcpQh[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFghcHK\|IH\vcIxwf2WmIHL5JGgzVzJiYXTkbZRqd25iZn;yJFIhcHK\|IHnuJJBz\XOnbnPlJI9nKGynb371dolv\SCkeTDFUGlUSQ>?	MlL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd3N{W0O\|EoRjJ5NUe1OFcyRC:jPh?=
H9c2	MVjDZZJlcW:ycn;0[YN1cX[nIHHzd4F6	NGjqRpgyKHWP	MUO4JIhzew>?	NY\v[JppS2G{ZHnvdJJwfGWldHn2[UBi[3Srdnn0fUBi\2GrboP0JIh6eG:6aXGtbY5lfWOnZDDvfIll[XSrdnWgd5Rz\XO\|IH3l[IlifGWmIHnu[oxidW2jdHnvckBqdiC{YYSgTFlkOiClZXzsd{Bie3Onc4Pl[EBieyC\|dYDwdoV{e2mxbjDv[kBKVC1zYnX0ZUBqdiC\|dYDldo5ifGGwdDDheEAyKHWPIIDy[Ylv[3WkYYTl[EBnd3JiODDodpMh\m:ubH;3[YQh[nliSELPNkBi\GSrdHnvckBnd3JiMjDodpMhcW5icILld4Vv[2Vib3[gcIVwdnW{aX7lJIJ6KEWO	NUTsOWJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke1O\|U1PzFpPkK3OVc2PDdzPD;hQi=>
H9c2	MkDoR4Fz\GmxcILveIVkfGm4ZTDhd5NigQ>?	NXTuZXlCOSC3TR?=	MkPOPEBpenN?	MmHZR4Fz\GmxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj5dI95cWFvaX7keYNm\CCleYTveI95cWOrdImgbY4hemG2IFi5Z\|Ih[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkh[XRiMTD1UUBxemWrbnP1ZoF1\WRiZn;yJFghcHK\|IH\vcIxwf2WmIHL5JGgzVzJiYXTkbZRqd25iZn;yJFIhcHK\|IHL5JG1VXCCjc4PhfS=>	M4PjcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NUe1OFcyLz5{N{W3OVQ4OTxxYU6=
RAW264.7	NEf3XGlCdnSraX7mcIFudWG2b4L5JIF{e2G7			MVfBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJI1wfXOnIGLBW\|I3PC55IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhVFCVLXnu[JVk\WRibnn0dolkKG:6aXTlJJBzd2S3Y4Tpc44h[nlibXXhd5VzcW6pIH7peJJqfGViYXPjeY12dGG2aX;uJIJ6KEe{aXXzd{Bu\XSqb3SsJGlEPTB;NEOuNu69VQ>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV4MUW4Okc,Ojh3NkG1PFY9N2F-
stem cells	NUDIbnd[TnWwY4Tpc44h[XO\|YYm=	MlPJNVAxKHWP	NF\w[Gg2KGSjeYO=	NGHVW4FKdmS3Y4Tpc44hd2ZiYXTpdI9o\W6nc3nzJIlvKGi3bXHuJIJwdmVibXHydo94NWSncnn2[YQhdWW\|ZX7jbJlu[Wxic4TlcUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjZHnwc45m[3SrbjDwdo9lfWO2aX;uJIF1KDFyMDD1UUBu\WG\|dYLl[EBwdiCmYYmgOUBqdiCycnXz[Y5k\SCxZjDJSHgh[nliRVzJV2E>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTN7OES0N{c,Ojl\|OUi0OFM9N2F-
DAOY	MULxTHRUKGG\|c3H5			MlHndWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	NH3JdHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh30	MoTKdWhVWyCjc4PhfS=>			MnLhdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN?	NGHrNWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NVLicpU2eUiWUzDhd5NigQ>?			M3zjR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	MkjuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
peritoneal cells	M2PXTWZ2dmO2aX;uJIF{e2G7		NGrwXIY2KGi{cx?=	NYm5SZRiUW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBRT0V{IIDyc4R2[3Srb36gbY4hSzV5Qly2JI1wfXOnIIDldol1d26nYXygZ4VtdHNibXXhd5Vz\WRiYYSgOUBpenNidHnt[UBqdnSnco\hcEBjgSCHTFnTRUwhUUN3ME20MlA5\|ryP	MlzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xO\|IoRjNyMEC2NVczRC:jPh?=
HCT8	NXnn[2h2SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MVm3NkBpenN?	NIrKUIJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFgh[2WubIOgZYZ1\XJiN{KgbJJ{KGmwIIDy[ZNmdmOnIH;mJINqdm6jbXHs[IVpgWSnIHL5JG1VXCCjc4PhfUwhUUN3ME2xOU43\|ryP	MoLnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{e0PVQoRjNyMEO3OFk1RC:jPh?=
RPMI8226	NXPz[Yo{S2WubDDjfYNt\SCjc4PhfS=>	NY\1fW8zOS55IIXN	Mlv5OFghcHK\|	M1q1b2NmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJHJRVUl6MkK2JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNE9IOSCyaHHz[UBifCBzLkegeW0hcW5icILld4Vv[2Vib3[gZo9zfGW8b33pZkBi\nSncjC0PEBpenNiYomgdJJweGmmaYXtJIlw\GmmZT;SUoF{\SC\|dHHpcolv\yCkYYPl[EBndG:5IHP5eI9u\XS{aXOgcYV1cG:mIILlcIF1cX[nIITvJIJwenSnen;tbYI>	MlHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB3OUCyOVgoRjNyNUmwNlU5RC:jPh?=
RPMI8226	NH\xT4tE\WyuIHP5Z4xmKGG\|c3H5	M{\FfFEvPyC3TR?=	M2DXbFQ5KGi{cx?=	MoHrR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gVnBOUTh{Mk[gZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IGOgdIhie2ViYYSgNU44KHWPIHnuJJBz\XOnbnPlJI9nKGKxcoTlfo9ucWJiYX\0[ZIhPDhiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUwWk6jc3Wgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dolkKG2ndHjv[EBz\WyjdHn2[UB1dyCkb4L0[ZpwdWmk	NET0Z5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEW5NFI2QCd-M{C1PVAzPTh:L3G+
RPMI8226	NEDTN45E\WyuIHP5Z4xmKGG\|c3H5	MWmxMlchfU1?	MYS0PEBpenN?	NGHZ[WhE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBTWE2LOEKyOkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iYXPjeY12dGG2aX;uJIF1KEd{L12gdIhie2ViYYSgNU44KHWPIHnuJJBz\XOnbnPlJI9nKGKxcoTlfo9ucWJiYX\0[ZIhPDhiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUwWk6jc3Wgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dolkKG2ndHjv[EBz\WyjdHn2[UB1dyCkb4L0[ZpwdWmk	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODV7MEK1PEc,OzB3OUCyOVg9N2F-
HaCaT	NWO3eJFbSW62aYD5doV1cWNiYYPzZZk>	M2PkOFExOCC3TR?=	MVuyJIhzew>?	NF\WfW1CdnSrcIny[ZRq[yCjY4Tpeol1gSCrbjDoeY1idiCKYVPhWEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGTOSoFteGijLXnu[JVk\WRiUFfFNkBxem:mdXP0bY9vKGG2IEGwNEB2VSCycnWtbY5kfWKjdHXkJIZweiB{IHjyd{Bj\W[xcnWgWG5H[WyyaHGgd5RqdXWuYYTpc44h\m:{IEK0JIhzeyCkeTDFUGlUSQ>?	NWfqPFRwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GzPVMyOjVpPkOxN\|k{OTJ3PD;hQi=>
OVCAR5	MnLtSpVv[3Srb36gZZN{[Xl?	MWizNFAhfU1idH:gNUBuVQ>?	MXm3NkBpenN?	MXjJcohq[mm2aX;uJI9nKE6DUGLUJIlvKGi3bXHuJG9XS0GUNTDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGK7IH3lZZN2emmwZzDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZZQhOzByIIXNJJRwKDFibV2gbY5kfWKjdHXkJIZweiB5MjDodpMh[nliU2LCJIF{e2G7	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
CCRF-CEM	NYHR[HpXTnWwY4Tpc44h[XO\|YYm=	MlqzN{42KG2P	MoDaOFghcHK\|	MknFTY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBES1KILVPFUUBk\WyuczDhd5Nme3OnZDDhd{Bxd3SnboTpZZRqd25ib3[gUmFOWFRiaX7obYJqfG:{IF\LPFY3NWmwZIXj[YQh[XCxcITvd4l{KGK7IH3lZZN2emmwZzDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZZQhOy53IH3NJJBz\XJvaX7jeYJifGWmIIfpeIghUUN3MDDs[ZZmdCCxZjDGT\|g3PiCob4KgOFghcHK\|IH\vcIxwf2WmIHL5JINwdXCxdX7kJIFl\Gm2aX;uJIFv\CCodYL0bIVz	M3vWOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
Jurkat	NIq3fZlHfW6ldHnvckBie3OjeR?=	MkXuN{42KG2P	NGqzbI01QCCqcoO=	MVrJcohq[mm2aX;uJI9nKE6DUGLUJIlvKGi3bXHuJGp2emujdDDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIk>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
ML2	Mn3ESpVv[3Srb36gZZN{[Xl?	M1\GdlMvPSCvTR?=	M2fXdlQ5KGi{cx?=	M{DQbWlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hVUx{IHPlcIx{KGG\|c3Xzd4VlKGG\|IIDveIVvfGmjdHnvckBw\iCQQV3QWEBqdmirYnn0c5IhTkt6Nk[tbY5lfWOnZDDhdI9xfG:\|aYOgZpkhdWWjc4XybY5oKHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjdDCzMlUhdU1icILldk1qdmO3YnH0[YQhf2m2aDDJR\|UxKGyndnXsJI9nKE[NOE[2JIZweiB2ODDodpMh\m:ubH;3[YQh[nliY3;tdI92dmRiYXTkbZRqd25iYX7kJIZ2enSqZYKgbY5kfQ>?	NXTJeVhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+
NOMO	MUjGeY5kfGmxbjDhd5NigQ>?	NEX4S3M{NjVibV2=	MYi0PEBpenN?	M2TadmlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hVk:PTzDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIlv[w>?	M1S0PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
NB4	NF61fodHfW6ldHnvckBie3OjeR?=	NWXTUo1POy53IH3N	NIWy[\|I1QCCqcoO=	NHvVNHVKdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKE6ENDDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIlv[3V?	NYjCeld5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+
NAMALWA	NXT6bFNTTnWwY4Tpc44h[XO\|YYm=	NIPSZlM{NjVibV2=	M1PhUFQ5KGi{cx?=	M1vDV2lvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hVkGPQVzXRUBk\WyuczDhd5Nme3OnZDDhd{Bxd3SnboTpZZRqd25ib3[gUmFOWFRiaX7obYJqfG:{IF\LPFY3NWmwZIXj[YQh[XCxcITvd4l{KGK7IH3lZZN2emmwZzDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZZQhOy53IH3NJJBz\XJvaX7jeYJifGWmIIfpeIghUUN3MDDs[ZZmdCCxZjDGT\|g3PiCob4KgOFghcHK\|IH\vcIxwf2WmIHL5JINwdXCxdX7kJIFl\Gm2aX;uJIFv\CCodYL0bIVz	Mn\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlUwLz6FaFXNRmw9N2F-
Daudi	M2PucWZ2dmO2aX;uJIF{e2G7	NHPIb5E{NjVibV2=	Moj6OFghcHK\|	NX[2W5BpUW6qaXLpeIlwdiCxZjDORXBTXCCrbjDoeY1idiCGYYXkbUBk\WyuczDhd5Nme3OnZDDhd{Bxd3SnboTpZZRqd25ib3[gUmFOWFRiaX7obYJqfG:{IF\LPFY3NWmwZIXj[YQh[XCxcITvd4l{KGK7IH3lZZN2emmwZzDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZZQhOy53IH3NJJBz\XJvaX7jeYJifGWmIIfpeIghUUN3MDDs[ZZmdCCxZjDGT\|g3PiCob4KgOFghcHK\|IH\vcIxwf2WmIHL5JINwdXCxdX7kJIFl\Gm2aX;uJIFv\CCodYL0bIVzKGmw	M4PzblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI2Nyd-Q3jFUWJNRC:jPh?=
Raji	M4\sW2Z2dmO2aX;uJIF{e2G7	NE\iVmY{NjVibV2=	NGTWN3Q1QCCqcoO=	M1mxdWlvcGmkaYTpc44hd2ZiTlHQVnQhcW5iaIXtZY4hWmGsaTDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIlv[w>?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
ARH77	MoHESpVv[3Srb36gZZN{[Xl?	MUGzMlUhdU1?	MUC0PEBpenN?	MlnBTY5pcWKrdHnvckBw\iCQQWDSWEBqdiCqdX3hckBCWkh5NzDj[YxteyCjc4Pld5Nm\CCjczDwc5RmdnSrYYTpc44hd2ZiTlHNVHQhcW6qaXLpeI9zKE[NOE[2MYlv\HWlZXSgZZBweHSxc3nzJIJ6KG2nYYP1dolv\yC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYYSgN{42KG2PIIDy[ZIucW6ldXLheIVlKHerdHigTWM2OCCuZY\lcEBw\iCIS{i2OkBnd3JiNEigbJJ{KG[xbHzve4VlKGK7IHPvcZBwfW6mIHHk[Il1cW:wIHHu[EBnfXK2aHXyJIlv	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?
RPMI8226	NUL5fnlHTnWwY4Tpc44h[XO\|YYm=	Mny2N{42KG2P	M17hSFQ5KGi{cx?=	MYjJcohq[mm2aX;uJI9nKE6DUGLUJIlvKGi3bXHuJHJRVUl6MkK2JINmdGy\|IHHzd4V{e2WmIHHzJJBwfGWwdHnheIlwdiCxZjDORW1RXCCrbnjpZol1d3JiRlu4OlYucW6mdXPl[EBieG:ydH;zbZMh[nlibXXhd5VzcW6pIILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDheEA{NjVibV2gdJJmei2rbnP1ZoF1\WRid3n0bEBKSzVyIHzleoVtKG:oIF\LPFY3KG[xcjC0PEBpenNiZn;scI94\WRiYomgZ49ueG:3bnSgZYRlcXSrb36gZY5lKG[3coTo[ZI>	NUnGXXJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjVxJ{7DbGVOSkx:L3G+
U266	MnrkSpVv[3Srb36gZZN{[Xl?	NVToeFBLOy53IH3N	MX60PEBpenN?	NGH6bnVKdmirYnn0bY9vKG:oIF7BVHJVKGmwIHj1cYFvKFV{Nk[gZ4VtdHNiYYPz[ZN{\WRiYYOgdI91\W62aXH0bY9vKG:oIF7BUXBVKGmwaHnibZRweiCIS{i2Ok1qdmS3Y3XkJIFxd3C2b4Ppd{BjgSCvZXHzeZJqdmdicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHH0JFMvPSCvTTDwdoVzNWmwY4XiZZRm\CC5aYToJGlEPTBibHX2[Ywhd2ZiRlu4OlYh\m:{IES4JIhzeyCob3zsc5dm\CCkeTDjc41xd3WwZDDh[IRqfGmxbjDhcoQh\nW{dHjldkBqdmN?	NEPzVXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPS9pPlPoSW1DVDxxYU6=
NAMALWA	MmL3SpVv[3Srb36gZZN{[Xl?	MonDN\|UhdWdxa3e=	MmDJOFUh\GG7cx?=	M1zXcXBwfGWwdHnheIlwdiCxZjDORW1RXCCrbnjpZol1d3JiMUCgcYcwc2duIHnwJIJq\CCIS{i2Ok1qdmS3Y3XkJIFvfGm2dX3vdkBi[3Srdnn0fUBqdiCqdX3hckBPSU2DTGfBJINmdGy\|IIjlco9oemGodHXkJIlvKFOFSVSgcY92e2ViYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hdW:3c3Wgd5Vzfmm4YXygZZQhOzVibXevb4ctKGmyIHLp[EB2eCC2bzC0OUBl[Xm\|	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyOU8oRkOqRV3CUFww[T5?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	SHH / SMO / GLI1 / Bcl-2 / Foxm1 ; PubMed: 28446712 Aging (Albany NY) Western blot analysis showed SHH, SMO, GLI1, Bcl-2 and Foxm1 proteins expression in U87 and T98G cells treated with indicated concentrations of aspirin for 24 h. GAPDH was used as an internal control. ; PubMed: 23741443 PLoS One Western blotting revealed that aspirin down-regulated COX1 and COX2 expression in HCC cell lines. p-AMPKα / AMPKα / p-ACC / ACC; PubMed: 26918349 Oncotarget Western blot analysis of the effects of aspirin on AMPK and ACC phosphorylation. p-AKT / AKT / p-ERK / ERK ; PubMed: 26918349 Oncotarget Western blot analysis of the effects of aspirin on Akt and ERK1/2 phosphorylation. MCL-1; PubMed: 26918349 Oncotarget Western blot analysis of the effects of aspirin on MCL-1 expression.	28446712 23741443 26918349
Growth inhibition assay	Cell viability; PubMed: 30221683 Int J Mol Med The CCK-8 assay results are presented as bar graphs for the antiproliferative effects of aspirin on RA-FLS. (A-C) RA-FLS were treated with (0, DMSO, 1, 2, 5 and 10 mM) aspirin for 12, 24 and 48 h. At each time interval, cell viability was determined by CCK-8 analysis. Data are presented as the means ± SD (error bars) from three independent experiments. Aspirin inhibited the growth of RA-FLS in a dose-dependent manner. (D) Cell proliferation decreased at 12, 24 and 48 h. Data are presented as the means ± SD (error bars) from three independent experiments. P<0.05, P<0.01, **P<0.001 vs. DMSO group. CCK-8: Cell-Counting Kit-8; RA-FLS, rheumatoid arthritis-fibroblast-like synoviocytes; DMSO, dimethyl sulfoxide; SD, standard deviation. Cell proliferation ; PubMed: 28446712 Aging (Albany NY) U87 and T98G cells were treated with indicated concentrations of aspirin and harvested after 24, 48 and 72 h. Cell proliferation was analyzed by CCK-8 assay.	30221683 28446712

Protocol

References

- Collapse

Solubility (25°C)

In vitro	DMSO	36 mg/mL (199.82 mM)
	Water	Insoluble
	Ethanol	''36 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+PBS For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Aspirin (NSC 27223) SDF

Molecular Weight	180.16
Formula	C₉H₈O₄
CAS No.	50-78-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Acetylsalicylic acid, ASA
Smiles	CC(=O)OC1=CC=CC=C1C(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04563546	Not yet recruiting	Other: Quality Improvement	Acute Coronary Syndrome	Duke University	January 1 2023	Not Applicable
NCT05031455	Not yet recruiting	Biological: Dupilumab\|Drug: Placebo	Aspirin-exacerbated Respiratory Disease	Scripps Clinic\|University of California San Diego\|Regeneron Pharmaceuticals	January 1 2022	Phase 2
NCT04308551	Not yet recruiting	Drug: Indobufen\|Drug: Aspirin	Stable Coronary Heart Disease	Henan Institute of Cardiovascular Epidemiology	December 30 2021	Not Applicable
NCT04974892	Not yet recruiting	Diagnostic Test: Blood test	Preeclampsia\|Neutrophil\|Immunology\|Pregnancy	Queen Mary University of London	September 1 2021	--
NCT04811625	Not yet recruiting	Drug: PL-ASA	Healthy Volunteers	PLx Pharma	May 2021	Phase 4
NCT04851964	Recruiting	Biological: Experimental: Tezepelumab\|Other: Placebo	Chronic Rhinosinusitis With Nasal Polyps	AstraZeneca\|Amgen	April 22 2021	Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

COX Signaling Pathway Map

Related COX Products

Xanthohumol ^New

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Xanthohumol inhibits diacylglycerol acyltransferase 1 (DGAT1) and DGAT2 with both IC50 of 40 μM. Xanthohumol is also a potent antiviral agent against a series of DNA and RNA viruses. Xanthohumol induces growth inhibition and apoptosis in cancer cells. Phase 1.
AZD3839 ^New

AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
Nirogacestat (PF-03084014) ^New

Nirogacestat (PF-03084014, PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Nirogacestat (PF-03084014, PF-3084014) induces apoptosis. Phase 2.
Celecoxib (SC 58635)

Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Indomethacin (NSC-77541)

Indomethacin (NSC-77541, Indometacin) is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.
Lornoxicam

Lornoxicam (Chlortenoxicam) is a non-steroidal COX-1/COX-2 inhibitor, used as an anti-inflammatory drug to treat pain, osteoarthritis, and rheumatoid arthritis.
Rofecoxib

Rofecoxib (MK-0966) is a COX-2 inhibitor with IC50 of 18 nM.
Ketorolac

Ketorolac is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).
Bufexamac

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

Features:A specific inhibitor of class IIB histone deacetylases.
Ibuprofen (NSC 256857)

Ibuprofen (NSC 256857, Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.

Features:Considered a core medicine in the WHO's "WHO Model List of Essential Medicines" (a list of the minimum medical requirements for a basic healthcare system).

Choose Your Country or Region

By Signaling Pathways

By product type

Aspirin (NSC 27223)